Opendata, web and dolomites

INNODIAB

Innovative diagnostic device for the early detection of diabetic neuropathy in diabetes patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "INNODIAB" data sheet

The following table provides information about the project.

Coordinator
VIBROSENSE DYNAMICS AB 

Organization address
address: MEDEON SCIENCE PARK PER ALBIN HANS
city: MALMO
postcode: 20512
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.the-diabetic-foot.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIBROSENSE DYNAMICS AB SE (MALMO) coordinator 50˙000.00

Map

 Project objective

The objective of the innovation project is to develop and clinically validate the first diagnostic device for the early detection of diabetic neuropathy (also referred to as diabetic foot). Diabetic foot is a common complication of both type 1 and type 2 diabetes. Current methods are only able to detect diabetic foot once the patient is already experiencing loss of sensation. This can result in an increased number of amputations and costs as a result of those amputations. The disruptiveness and the market potential of the new device lie in its capacity to identify diabetic neuropathy at a very early stage. The device will fill the identified niche on the market and contribute to better clinical outcomes for the patients. The main need of the users (physicians, nurses, policy makes, and patients) is access to an efficient dependable method for early detection of diabetic neuropathy. These needs will be met through the prototype device allowing physicians and nurses to assess the condition and determine appropriate treatment. The Phase 1 project will develop a strategic business plan for the commercialisation of the innovative diagnostic device for the early detection of diabetic neuropathy. The project will strengthen VibroSense’s understanding of the European market in general and verify the economic viability of the clinical validation to be pursued within the Phase 2 project. The late diagnosis of diabetic foot results in patient’s suffering and substantial health-care costs. It is estimated that approximately 1/9 of the total healthcare expenditures in Europe is spent on diabetes, with foot care being one of the more dominant costs. The project addresses this EU-wide challenge by proposing a new early-diagnostic method. The new device will build a strong case for introducing more cost-effective, personalised medicine approaches in the management of diabetic foot. The commercial output will be new competitive advantages and accelerated growth for VibroSense.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INNODIAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INNODIAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More